Senolytics for Cognition, Tirzepatide for HFpEF, and Exosome Therapy for Knees

Senescent cells are old, dysfunctional cells that linger in tissues and pump out inflammatory molecules. They accumulate with age and are thought to be a driver of aging itself. Senolytics are drugs designed to identify and kill these cells selectively.

Two 2025 trials—SToMP-AD and STAMINA—gave older adults with cognitive decline a combination of dasatinib (a cancer drug) plus quercetin (a plant compound) for 12 weeks. SToMP enrolled 5 people with symptomatic Alzheimer's disease; STAMINA enrolled 12 with mild cognitive impairment and slow walking speed. Both trials showed that the drug combination was safe, reduced inflammatory markers in the blood, and lowered signs of senescence-linked inflammation. In STAMINA, people with the lowest cognitive scores at the start saw an average 2-point improvement in thinking tests—a modest signal that warrants larger study.

The promise is real but remains early. These trials are tiny, open-label (not placebo-controlled), and lack objective biomarkers of senescence to confirm the mechanism. But the safety record is clean, and the reduction in brain-accessible inflammatory markers offers a plausible path forward for cognitive aging.

Heart failure with preserved ejection fraction, or HFpEF, is a condition where the heart muscle does not pump weakly but becomes stiff and resists filling with blood. It is especially common in older adults and people with obesity, and it has few approved treatments.

The SUMMIT trial, published in 2024 with follow-up analyses in 2025, randomized 731 patients with HFpEF and a BMI over 30 to receive tirzepatide or placebo weekly for a median of two years. Tirzepatide reduced the combined risk of worsening heart failure—meaning hospitalization, urgent IV therapy, or need to intensify water pills—by 46 percent. The drug also lowered blood pressure, reduced signs of fluid overload at 52 weeks, and improved exercise tolerance and quality-of-life scores.

Tirzepatide is a peptide that activates two receptors: GLP-1 and GIP. Most of the benefit appears to stem from weight loss, but secondary analyses suggest additional mechanisms, such as reduced inflammation and improved heart muscle stiffness. This is the first major breakthrough therapy for HFpEF in years, and the trial opens a new path for treating a common and previously intractable form of heart failure.

Mesenchymal stem cells, or MSCs, are multipurpose cells found in bone marrow, fat, and other tissues. They can calm inflammation and support tissue repair. One drawback of transplanting whole MSCs is poor survival and risk of unwanted effects. Exosomes—tiny packages of proteins, lipids, and RNA that cells release—carry many of the MSC's healing signals without those risks.

A 2025 systematic review and meta-analysis of 28 preclinical studies found that MSC-derived exosomes reduced cartilage damage and inflammation in animal models of knee osteoarthritis. Clinical trials using exosomes from umbilical-cord-derived MSCs have begun, and early reports show they are safe and linked to pain relief and modest functional improvement. However, imaging studies have not yet shown reliable cartilage regrowth in humans.

The bottleneck is standardization. Different clinics and researchers prepare and dose exosomes differently, making it hard to compare results or predict what will work. The preclinical signal is strong, and the clinical safety record is clean, but the field needs agreed-upon standards and larger randomized trials before exosome therapy can graduate from experimental to routine care.